XORTX Therapeutics Inc. (XRTX.V)
CAD 1.62
(-7.43%)
CAD 1.62
(-7.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.53 Million CAD | 56.14% |
| 2022 | -10.33 Million CAD | 30.13% |
| 2021 | -14.78 Million CAD | -8532.55% |
| 2020 | -171.27 Thousand CAD | -2095.5% |
| 2019 | -7801.00 CAD | 96.4% |
| 2018 | -216.76 Thousand CAD | -202.96% |
| 2017 | 210.52 Thousand CAD | 96.1% |
| 2016 | 107.35 Thousand CAD | 0.0% |
| 2014 | -762.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.82 Million USD | -11.21% |
| 2024 Q2 | -2.99 Million USD | 21.63% |
| 2023 Q4 | -3.43 Million USD | 31.83% |
| 2023 FY | -4.53 Million CAD | 56.14% |
| 2023 Q1 | -7.84 Million USD | 44.03% |
| 2023 Q2 | -6.11 Million USD | 22.02% |
| 2023 Q3 | -5.04 Million USD | 17.62% |
| 2022 Q1 | -15.5 Million CAD | 17.73% |
| 2022 Q4 | -14.02 Million CAD | -16.51% |
| 2022 FY | -10.33 Million CAD | 30.13% |
| 2022 Q3 | -12.03 Million CAD | 9.34% |
| 2022 Q2 | -13.27 Million CAD | 14.42% |
| 2021 Q4 | -18.85 Million CAD | -277.21% |
| 2021 Q3 | -4.99 Million CAD | 2.93% |
| 2021 Q2 | -5.14 Million CAD | 14.81% |
| 2021 FY | -14.78 Million CAD | -8532.55% |
| 2021 Q1 | -6.04 Million CAD | -3428.76% |
| 2020 FY | -171.27 Thousand CAD | -2095.5% |
| 2020 Q2 | -313.38 Thousand CAD | 31.59% |
| 2020 Q1 | -458.13 Thousand CAD | -5772.71% |
| 2020 Q4 | -171.27 Thousand CAD | 9.42% |
| 2020 Q3 | -189.09 Thousand CAD | 39.66% |
| 2019 Q2 | -52.42 Thousand CAD | 46.31% |
| 2019 FY | -7801.00 CAD | 96.4% |
| 2019 Q1 | -97.63 Thousand CAD | 54.96% |
| 2019 Q4 | -7801.00 CAD | 86.91% |
| 2019 Q3 | -59.57 Thousand CAD | -13.66% |
| 2018 Q4 | -216.76 Thousand CAD | 37.54% |
| 2018 Q2 | -556.39 Thousand CAD | 33.26% |
| 2018 Q3 | -347.02 Thousand CAD | 37.63% |
| 2018 Q1 | -833.66 Thousand CAD | -495.99% |
| 2018 FY | -216.76 Thousand CAD | -202.96% |
| 2017 Q2 | -133.74 Thousand CAD | 28.01% |
| 2017 Q4 | 210.52 Thousand CAD | 60.34% |
| 2017 FY | 210.52 Thousand CAD | 96.1% |
| 2017 Q1 | -185.78 Thousand CAD | 16.94% |
| 2017 Q3 | 131.3 Thousand CAD | 198.17% |
| 2016 Q4 | -223.68 Thousand CAD | -26948.13% |
| 2016 Q3 | -827.00 CAD | 88.43% |
| 2016 Q2 | -7147.00 CAD | 80.48% |
| 2016 Q1 | -36.6 Thousand CAD | 49.86% |
| 2016 FY | 107.35 Thousand CAD | 0.0% |
| 2015 Q4 | -73.01 Thousand CAD | -4816.57% |
| 2015 Q3 | -1485.00 CAD | 83.34% |
| 2015 Q2 | -8916.00 CAD | -1070.08% |
| 2015 Q1 | -762.00 CAD | 0.0% |
| 2014 FY | -762.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 4.18 Million CAD | 208.268% |
| Covalon Technologies Ltd. | -7.23 Million CAD | 37.351% |
| Hemostemix Inc. | 4.16 Million CAD | 208.757% |
| Universal Ibogaine Inc. | 1.01 Million CAD | 547.884% |
| Kane Biotech Inc. | 7.52 Million CAD | 160.198% |
| MedMira Inc. | 9.25 Million CAD | 148.94% |
| Marvel Biosciences Corp. | 443.37 Thousand CAD | 1121.908% |
| NervGen Pharma Corp. | -11.46 Million CAD | 60.471% |